These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12115361)

  • 1. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
    Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
    Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience.
    Kim DH; Kim SY; Lee HJ; Song BS; Kim DH; Cho JB; Lim JS; Lee JA
    Cancer Res Treat; 2011 Sep; 43(3):170-5. PubMed ID: 22022294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
    Hawkins DS; Schuetze SM; Butrynski JE; Rajendran JG; Vernon CB; Conrad EU; Eary JF
    J Clin Oncol; 2005 Dec; 23(34):8828-34. PubMed ID: 16314643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
    Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
    Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
    Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
    Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression.
    Sato J; Yanagawa T; Dobashi Y; Yamaji T; Takagishi K; Watanabe H
    Clin Exp Metastasis; 2008; 25(4):427-35. PubMed ID: 18301993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
    Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
    Ye Z; Zhu J; Tian M; Zhang H; Zhan H; Zhao C; Yang D; Li W; Lin N
    Ann Nucl Med; 2008 Jul; 22(6):475-80. PubMed ID: 18670853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
    Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
    Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
    Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
    J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
    Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
    Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
    Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
    Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
    Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
    J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
    Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
    Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis.
    Franzius C; Sciuk J; Brinkschmidt C; Jürgens H; Schober O
    Clin Nucl Med; 2000 Nov; 25(11):874-81. PubMed ID: 11079583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
    Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.